“GENESIS LABORATORIES” Ltd. operating in „Manufacturing of medical drug substances" is specialized in the production of lyophilised products - yeast and probiotic nutritional supplements. “GENESIS LABORATORIES” Ltd. needs to address increased customer demand at the limitation of full production capacity utilization, as well as to improve the quality and competitiveness of products, in order to expand its positions on the international markets. The company is using physically old and outdated equipment, which is not efficient enough and lead to labor intensive production with high energy and material consumption, and unstable parameters of production processes. In order for these needs to be met, the project provides for the purchase of fixed assets, representing a completely new solution: 1 Lyophilisator, 1 Production line for tableting, blistering and counting and 1 Vertical packaging machine. The new equipment will increase capacity, improve export capabilities and will ensure precise production parameters, which will enhance resource efficiency and effectiveness in production processes, and will decrease cost of production per unit. The company is in the range of eligible target group with a project in ISSS thematic field “Industry for healthy life and biotechnologies” and activities for adopting new technologies for improving resource efficiency and effectiveness in production processes. The expected results are: improving competitiveness and creating export potential, decreasing production cost and increasing production capacity. The project is directed to the following activities: improvement of production processes as well as introduction of new technologies for enhanced resource efficiency and effectiveness in production process, as well as improving the quality of currently produced products.
Overview
Status | Closed (completion date) |
---|---|
Start date | 09 Feb, 2016 |
End date | 22 Mar, 2017 |
Contract date | 09 Feb, 2016 |
Programme
Beneficiary
Financial information
Total cost | 1,665,781.00 |
---|---|
Grant | 749,601.45 |
Self finance | 916,179.55 |
Total paid | 749,601.00 |
EU participation percent | 85.0% |
Location